Highlights

  • Nyrada shares increased 4.31% on 15 April 2026 following quarterly update.
  • Human Research Ethics Committee approved Phase IIa trial for Xolatryp.
  • Patient recruitment for the trial set to begin in April 2026.
  • Preclinical studies initiated to explore oncology applications.
  • Cash balance stood at AU$6.74 million as of 31 March 2026.

Nyrada Inc (ASX:NYR) shares rose 4.31% to AUD 0.60 on 15 April 2026, extending its one-year gain to 404.17%. Today’s upward movement follows the release of the company’s March 2026 quarterly activities report, which outlined progress across its clinical and research programs.

The update highlights a key milestone for Nyrada’s lead drug candidate, Xolatryp, with regulatory approval secured to move forward into the next stage of clinical development.

Company Overview: Focused on TRPC Ion Channel Therapies

Nyrada is a clinical-stage biotechnology company focused on developing small-molecule therapies targeting Transient Receptor Potential Canonical (TRPC) ion channels. These channels play a role in calcium regulation within cells, which is linked to various medical conditions.

The company’s lead program, Xolatryp, is designed to inhibit calcium ion influx through TRPC 3/6/7 channels. This mechanism aims to protect cellular function, particularly in conditions involving tissue damage such as heart attacks.

Nyrada’s pipeline includes applications in cardiovascular and neurological conditions, with additional research exploring potential benefits in oncology.

Phase IIa Trial Approval Marks Key Clinical Progress

During the March 2026 quarter, Nyrada received approval from the Human Research Ethics Committee (HREC) to conduct a Phase IIa clinical trial for Xolatryp.

The trial will assess the safety and preliminary efficacy of the drug candidate in patients who have experienced a heart attack and are undergoing angioplasty with stenting, also known as percutaneous coronary intervention (PCI).

Patient recruitment for the study is scheduled to begin in April 2026, with initial hospital trial sites already confirmed.

The study is designed as a randomised, double-blind, placebo-controlled trial, with safety as the primary endpoint. In addition, multiple secondary and exploratory endpoints will be evaluated, including cardiac function, extent of cardiac injury, biomarker levels such as troponin I, and the occurrence of arrhythmias.

Due to the study design, efficacy data will only be available after completion of the trial. However, the company intends to provide periodic updates on recruitment progress and safety assessments.

Advancing Regulatory Pathway in the United States

In parallel with clinical trial preparations, Nyrada has commenced work on an Investigational New Drug (IND) application for submission to the U.S. Food and Drug Administration (FDA).

This application is intended to support the company’s myocardial ischemia reperfusion injury program, further advancing its regulatory pathway in a key global market.

The preparation of the IND submission represents an additional step in positioning the program for broader clinical development.

Expansion into Oncology Research

Beyond its cardiovascular focus, Nyrada has initiated preclinical studies to evaluate the potential of Xolatryp in oncology applications.

These studies are exploring whether the drug candidate may provide cardioprotective benefits in patients undergoing chemotherapy, particularly those treated with anthracycline drugs such as doxorubicin.

Doxorubicin is widely used in cancer treatment but is associated with a risk of cardiac damage, especially at higher cumulative doses. Scientific literature referenced by the company suggests that Xolatryp may help reduce this risk by protecting cardiac function.

The company indicated that it will provide updates as further data becomes available from these studies.

Intellectual Property Progress

Nyrada also reported progress on its intellectual property strategy, with its composition of matter patent application published during the quarter.

The patent, originally submitted in September 2024, is expected—subject to approval—to provide 20 years of intellectual property protection from the priority date.

The publication of the patent represents a key step in the patent approval process, which typically takes several years to complete.

Financial Position and Cash Flow

As at 31 March 2026, Nyrada reported a cash balance of AU$6.74 million, compared to AU$7.12 million at the end of December 2025.

Total cash operating outflows for the quarter were approximately AU$970,000, partially offset by AU$80,000 in interest income.

The company also received AU$0.51 million from the exercise of options during the period.

Payments to related parties totalled approximately AU$219,000, including director fees and executive remuneration.

In addition, Nyrada expects to receive an R&D tax incentive refund of AU$2.45 million for the financial year ended 30 June 2025. This represents an increase from the previously estimated AU$2.16 million.

The company noted that the refund has been delayed due to the timing of regulatory approvals but is expected to be received before the end of the 2026 financial year.

About Xolatryp and Clinical Background

Xolatryp is a small-molecule therapy designed to limit pathological calcium entry into cells by inhibiting TRPC ion channels.

This mechanism is intended to protect mitochondrial function and reduce damage associated with ischemia reperfusion injury, which occurs when blood supply returns to tissue after a period of oxygen deprivation, such as during a heart attack.

The drug has already completed a Phase I clinical trial, which assessed safety, tolerability, and pharmacokinetics.

The upcoming Phase IIa study will build on this foundation, focusing on safety and preliminary efficacy in a clinical setting involving heart attack patients undergoing PCI.

What This Means for Investors?

The March 2026 quarterly update highlights continued progress in Nyrada’s clinical development pathway, particularly with the transition of Xolatryp into a Phase IIa trial.

The approval from the Human Research Ethics Committee and the commencement of patient recruitment appear to be supporting the share price movement observed on 15 April 2026.

In addition, the expansion into oncology research, progress on regulatory filings, and updates on intellectual property contribute to the company’s broader development strategy.

With multiple milestones expected, including trial recruitment updates and potential data releases, investors are likely to monitor the progression of the clinical program over the coming periods.